CompoAtlas

THALAMAG Sérénité Jour et Nuit

Food supplement declared in France, declaration No 2021-9-18

THALAMAG Sérénité Jour et Nuit, from BIOCODEX, is a food supplement declared in France. Status: withdrawn from the market on 28 November 2024. Main ingredients: Valeriana officinalis 120 mg per day, Paullinia cupana 75 mg per day, Magnesium, Vitamin C. 1 rule of use applies to its ingredients (limits and warnings).

Brand
THALAMAG
Food business operator placing the product on the market
BIOCODEX
Status
Withdrawn from the market on 28 November 2024
Form
Tablet
Daily dose
1 comprimé jour et 1 comprimé nuit.
Directions for use
1 comprimé jaune (jour) le matin et 1 comprimé bleu (nuit) le soir à avaler avec un verre d’eau.
Intended populations
Adolescents aged 11 to 17, People over 60, Men, Women
Not recommended (according to the manufacturer)
Breastfeeding women, Pregnant women, Infants (under 1 year)
Objectives stated by the manufacturer (these are not authorised claims)
Sleep, Nervous system

Declaration 284703, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Valeriana officinalis L.RacineAutre extrait sec120 mg
Paullinia cupana KunthGraineAutre extrait sec75 mg

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
magnesium hydroxideMagnesium250 mg300 mg
L-ascorbic acidVitamin Cno limit (insufficient data)180 mg

Additives

E460, E341, E1201, E470b, E551, E464, E570, E422, E330, E414

Other ingredients

Spirulina major Kützing ex Gomont, Concentré de carthame, maltodextrine

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Ne pas dépasser la dose journalière recommandée. Tenir hors de portée des jeunes enfants. Ne se substitue pas à une alimentation variée, équilibrée et à un mode de vie sain. Na pas consommer en cas de sensibilité connue à l'un des constituants. Contient de la caféine (13 mg), déconseillé aux enfants et aux femmes enceintes. Peut entrainer des effets laxatifs.Conserver à l'abris de la chaleur et de l'humidité.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Valeriana officinalis L.
    Read the warning, when it applies and the studies cited

    Valerian - VALERIANA OFFICINALIS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Mills et al. 2006; Blumenthal et al. 2003; Barnes et al. 2002).

    Sources cited by Health Canada (3)
    • Barnes J, Anderson LA, Phillipson JD. Herbal Medicines: A guide for healthcare professionals. 2nd ed. London (UK): Pharmaceutical Press; 2002.
    • Blumenthal M, Hall T, Goldberg A, Kunz T, Dinda K, Brinckmann J, Wollschlaeger B, editors. 2003. The ABC Clinical Guide to Herbs: Valerian. Austin, Texas: American Botanical Council.
    • Mills E, Dugoua J, Perri D, Koren G. 2006. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (GB): Taylor and Francis Medical.

    When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010; Gennaro et al. 2000).

    Sources cited by Health Canada (2)
    • Gennaro AR, Marderosian AHD, Hanson GR, Medwick T, editors. 2000. Remington: The Science and Practice of Pharmacy, 20th edition. Philadelphia (PA): Lippincott Williams & Wilkins.
    • Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications. 2010.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2016; ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (3)
    • Bradley PR, editor. 1992. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (GB): British Herbal Medicine Association.
    • EMA 2016. European Medicines Agency. Community Monograph on Valeriana Officinalis L., Radix. London (GB): EMEA Committee on Herbal Medicinal Products (HMPC), 02 Febuary 2016. [Accessed 2023 October 27]. Available from: https://www.ema.europa.eu/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (EMA 2016; Berardi et al. 2002; Dipiro et al. 2002).

    Sources cited by Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. 2002. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association.
    • Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. 2002. Pharmacotherapy: A Pathophysiologic Approach, 5th edition. New York (NY): The McGraw-Hill Companies, Inc.
    • EMA 2016. European Medicines Agency. Community Monograph on Valeriana Officinalis L., Radix. London (GB): EMEA Committee on Herbal Medicinal Products (HMPC), 02 Febuary 2016. [Accessed 2023 October 27]. Available from: https://www.ema.europa.eu/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf

    Condition of application: Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 26 July 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : THALAMAG

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “THALAMAG Sérénité Jour et Nuit: composition and regulation”, https://compoatlas.com/en/supplements/products/284703-thalamag-serenite-jour-et-nuit, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line